

BE THE GENERATION

TO END THE HIV EPIDEMIC

FROM THE EDITOR

protest: pro + *testari* (publicly + assert/witness)


I don't shout when I'm easily heard
Only when you won't listen
Because the door is barred, blinders are on, mufflers are set
Because I'm here and you won't know it
I must
assert publicly
my being. It
means you will witness my existence
publicly
You may witness me at Stonewall
when there was no choice left but to Uprise
It forced you to see me
It made room for our Pride
and its tactics, and Stonewall and theirs
gave rise to HIV activism and protest, too
The protest for queer rights is
the protest for HIV rights is
the protest for science is
the public assertion of what is already true
That you are me and I am you

Cat Banobi, Project Manager &
The Legacy Project

KEEP IN TOUCH

Email us at btg@hanc.info &

Follow the Legacy Project at:

 [@hanc_legacy](https://www.instagram.com/hanc_legacy)

 [Legacy Project](https://www.facebook.com/legacyproject)

 [@hanc-legacyproject](https://twitter.com/hanc-legacyproject)






HIV VACCINE
TRIALS NETWORK

NETWORK NEWS

HIV VACCINE TRIALS NETWORK (HVTN)

The HVTN has released a video story of the remarkable scientific and human achievements from the last 25 years that personify the organization we call the HVTN. It is a celebration of the researchers, advocates, community leaders and institutions that have contributed to our work over 25 years. You can see the film [here](#), as well as short video segments that dive deeper into particular themes.



Additionally, as we celebrate the anticipated approval of Lenacapavir in the coming months as another method of long-acting injectable PrEP, leaders from the HVTN have made the argument for why a vaccine against HIV is still relevant, important, and something the world still needs as an essential item in the HIV prevention toolbox. You can read their Perspective article in the *New England Journal of Medicine* [here](#).



Cat Banobi here, writing with some of my own reflections on recent work from IMPAACT. In March, the network published an [article](#) in The Lancet about IMPAACT 2017/MOCHA which was a study of long-acting injectable cabotegravir and rilpivirine among adolescents. I was delighted to see this work be published for several reasons.

First, the fact that it was a study designed specifically for adolescents. To end the epidemic, it is essential to study and develop prevention and treatment options that are tailored to different populations. Thanks to IMPAACT 2017/MOCHA, we are one step closer to injectable treatment for adolescents living with HIV.

Second, this trial was published not long after the Adolescent Trials Network (ATN) was [dismantled](#) (and then partly restored). The reduction of the ATN was devastating; adolescents are still living with and have the potential to acquire HIV, and we are still responsible for helping them. The sudden reduction of a research network dedicated to young people means that the focus on adolescents will need to come from elsewhere. Studies like this one from IMPAACT will meet that need.

And finally, the results are positive! The study found that there were no unexpected side effects and that the injectable treatment worked similarly in adolescents as in adults (this treatment has already been approved for use in adults). This moves us one step closer to a fully intramuscular injectable treatment for adolescents living with HIV...and one step closer to ending the HIV epidemic.



HPTN HIV Prevention
Trials Network

NETWORK NEWS

HIV PREVENTION TRIALS NETWORK (HPTN)

It's Cat again, this time with reflections on a recent update from the HPTN where the theme of key populations continues. The network recently announced fantastic enrollment progress for two ongoing studies of the twice-yearly injectable drug, Lenacapavir, for HIV prevention: [HPTN 102/PURPOSE 3](#) and [HPTN 103/PURPOSE 4](#). HPTN 102 has reached 50% enrollment and HPTN 103 has passed 70%! With this progress, these trials are well on their way to contributing to our understanding of the effectiveness of Lenacapavir for two priority populations: cisgender women in the United States (HPTN 102) and people who inject drugs (HPTN 103).

As a member of the Legacy Project, which aims to improve representation of underrepresented groups in HIV research, these studies and others like them make me so hopeful. Such studies, ones that are designed thoughtfully and intentionally to prioritize populations who are underrepresented in research and overrepresented in the epidemic, are the key for ensuring that we have a wealth of treatment and prevention options that work for people who need them the most. [Two previous studies](#) of lenacapavir with other key populations showed that the product was extremely effective; I am hopeful that HPTN 102 and 103 will be similarly positive and that we will be another big step forward towards long-acting prevention for many more people who need it.



HPTN 102
PURPOSE 3

AND



HPTN 103
PURPOSE 4



hanc
HIV/AIDS Network Coordination

HANC RESOURCES

OFFICE OF HIV/AIDS NETWORK COORDINATION (HANC)

RESOURCES

Be the Generation website: the best place to go for trustworthy information on HIV prevention research. Features sections on PrEP, U=U, microbicides, HIV vaccine research, inspiring videos from researchers and community members, and even a quiz to test your knowledge of HIV prevention research.

The H=H Podcast: The podcast that centers on the 'Human' in 'HIV.' This podcast is sponsored by the HANC Legacy Project and presents content on the human side of research, featuring scientists, community members, and affirming communities disproportionately affected by HIV.

Webinar Library: a collection of webinar recordings on topics such as HIV & race, HIV & women, HIV genetic sequencing, HIV & aging, outreach & marketing, Native Americans & HIV, microbicides research, pregnancy & lactation in HIV research, HIV in the Latinx community, community engagement, Monkeypox, and more.

Transgender Training Resources Homepage: the Division of AIDS at the National Institute of Allergy and Infectious Diseases has put all its amazing resources related to research with transgender people in one place. All resources are free; you just need to create a free account if you don't have one already.

IMPORTANT DATES

June 1: Pride Month begins

June 2-4: HPTN Annual Meeting (virtual; application required)

June 5: HIV Long-Term Survivors Awareness Day

June 19: Juneteenth

June 24-28: ACTG Annual Meeting (virtual; application required)

June 27: National HIV Testing Day

July 13-17: IAS Conference on HIV Science in Kigali, Rwanda

July 21: Zero HIV Stigma Day

August 20: Southern HIV/AIDS Awareness Day

August 25: National Faith HIV/AIDS Awareness Day

September 4-7: United States Conference on HIV/AIDS in Washington, DC

September 7-12: IMPAACT Annual Meeting (virtual; application required)